RPS6KA3(RSK2)
Sign in to save this workspaceUniProt P51812 · PDB · AlphaFold · Substrate: Glycogen Synthase-derived peptide · Clone: full length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Midostaurin | 95.8% | 4.2% | 78.64 | 0.500 |
| 2 | Brigatinib | 95.2% | 4.8% | 82.96 | 0.513 |
| 3 | Netarsudil | 89.1% | 10.9% | 93.22 | 0.676 |
| 4 | Rabusertib | 76.2% | 23.8% | 98.74 | 0.687 |
| 5 | Capivasertib | 75.2% | 24.8% | 96.48 | 0.644 |
| 6 | Sunitinib | 54.1% | 45.9% | 91.73 | 0.524 |
| 7 | Ceritinib | 52.0% | 48.0% | 95.44 | 0.618 |
| 8 | Defactinib | 50.4% | 49.6% | 92.68 | 0.450 |
| 9 | Gilteritinib | 38.8% | 61.2% | 88.97 | 0.506 |
| 10 | Darovasertib | 30.8% | 69.2% | 96.99 | 0.719 |
| 11 | Nintedanib | 29.5% | 70.5% | 90.23 | 0.608 |
| 12 | Bosutinib | 27.8% | 72.2% | 87.22 | 0.555 |
| 13 | Alectinib | 25.3% | 74.7% | 95.49 | 0.651 |
| 14 | Axitinib | 23.0% | 77.0% | 93.23 | 0.688 |
| 15 | Ponatinib | 22.7% | 77.3% | 78.23 | 0.534 |
| 16 | Fostamatinib | 21.2% | 78.8% | 96.74 | 0.613 |
| 17 | Selpercatinib | 20.1% | 79.9% | 96.72 | 0.635 |
| 18 | Upadacitinib | 17.3% | 82.7% | 97.98 | 0.663 |
| 19 | Fedratinib | 16.3% | 83.7% | 96.21 | 0.576 |
| 20 | Abrocitinib | 15.4% | 84.6% | 99.50 | 0.581 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 4.47
- Epithelial log2(TPM+1): 3.94
- Fold change: 0.53
- Status: No significant change
Selectivity landscape vs inhibition on RPS6KA3
Each point is one of the 92 approved drugs; color = inhibition % on RPS6KA3.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…